Current drug targets最新文献_第3页

Chitosan-Based Nanocarriers for Pulmonary and Intranasal Drug Delivery Systems: A Comprehensive Overview of their Applications 用于肺部和鼻内给药系统的壳聚糖基纳米载体：应用综述

IF 3.2 4区医学

Current drug targets Pub Date : 2024-04-27 DOI: 10.2174/0113894501301747240417103321

Wasan Alwahsh, Shariza Sahudin, Hatim Alkhatib, Mohammad F. Bostanudin, Mohammad Alwahsh

{"title":"Chitosan-Based Nanocarriers for Pulmonary and Intranasal Drug Delivery Systems: A Comprehensive Overview of their Applications","authors":"Wasan Alwahsh, Shariza Sahudin, Hatim Alkhatib, Mohammad F. Bostanudin, Mohammad Alwahsh","doi":"10.2174/0113894501301747240417103321","DOIUrl":"https://doi.org/10.2174/0113894501301747240417103321","url":null,"abstract":": The optimization of respiratory health is important, and one avenue for achieving this is through the application of both Pulmonary Drug Delivery System (PDDS) and Intranasal Delivery (IND). PDDS offers immediate delivery of medication to the respiratory system, providing advantages, such as sustained regional drug concentration, tunable drug release, extended duration of action, and enhanced patient compliance. IND, renowned for its non-invasive nature and swift onset of action, presents a promising path for advancement. Modern PDDS and IND utilize various polymers, among which Chitosan (CS) stands out. CS is a biocompatible and biodegradable polysaccharide with unique physicochemical properties, making it well-suited for medical and pharmaceutical applications. The multiple positively charged amino groups present in CS facilitate its interaction with negatively charged mucous membranes, allowing CS to adsorb easily onto the mucosal surface. In addition, CS-based nanocarriers have been an important topic of research. Polymeric Nanoparticles (NPs), liposomes, dendrimers, microspheres, nanoemulsions, Solid Lipid Nanoparticles (SLNs), carbon nanotubes, and modified effective targeting systems compete as important ways of increasing pulmonary drug delivery with chitosan. This review covers the latest findings on CS-based nanocarriers and their applications.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":"28 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140810099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Recent Advances in the Function and Mechanism of Caveolin-1 in Retinal Neovascularization 视网膜新生血管中 Caveolin-1 功能和机制的最新研究进展

IF 3.2 4区医学

Current drug targets Pub Date : 2024-04-09 DOI: 10.2174/0113894501310201240403065930

Rui Zhang, Yalong Dang

引用次数: 0

Cisplatin-Based Combination Therapy for Enhanced Cancer Treatment 加强癌症治疗的顺铂联合疗法

IF 3.2 4区医学

Current drug targets Pub Date : 2024-04-09 DOI: 10.2174/0113894501294182240401060343

Qi Li, Siwei Chen, Xiao Wang, Jia Cai, Hongwu Huang, Shengsong Tang, Dongxiu He

引用次数: 0

Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database 利用 FDA 不良事件报告系统 (FAERS) 数据库进行药物再利用

IF 3.2 4区医学

Current drug targets Pub Date : 2024-04-03 DOI: 10.2174/0113894501290296240327081624

Robert Morris, Feng Cheng, Rahinatu Ali

引用次数: 0

Skin Microbial Composition and Genetic Mutation Analysis in Precision Medicine for Epidermolysis Bullosa 表皮松解症精准医疗中的皮肤微生物组成和基因突变分析

IF 3.2 4区医学

Current drug targets Pub Date : 2024-04-03 DOI: 10.2174/0113894501290512240327091531

Inna Syafarina, Maulida Mazaya, Ariani Indrawati, Sharfina Zahra Akbar, Rifki Sadikin, Caecilia Sukowati

{"title":"Skin Microbial Composition and Genetic Mutation Analysis in Precision Medicine for Epidermolysis Bullosa","authors":"Inna Syafarina, Maulida Mazaya, Ariani Indrawati, Sharfina Zahra Akbar, Rifki Sadikin, Caecilia Sukowati","doi":"10.2174/0113894501290512240327091531","DOIUrl":"https://doi.org/10.2174/0113894501290512240327091531","url":null,"abstract":": Epidermolysis bullosa (EB) is an inherited skin disease representing a spectrum of rare genetic disorders. These conditions share the common trait that causes fragile skin, resulting in the development of blisters and erosions. The inheritance follows an autosomal pattern, and the array of clinical presentations leads to significant physical suffering, considerable morbidity, and mortality. Despite EB having no cure, effectively managing EB remains an exceptional challenge due to its rarity and complexity, occasionally casting a profound impact on the lives of affected individuals. Considering that EB management requires a multidisciplinary approach, this sometimes worsens the condition of patients with EB due to inappropriate handling. Thus, more appropriate and precise treatment management of EB is essentially needed. Advanced technology in medicine and health comes into the bioinformatics era. Including treatment for skin diseases, omics-based approaches aim to evaluate and handle better disease management and treatment. In this work, we review several approaches regarding the implementation of omics-based technology, including genetics, pathogenic mutation, skin microbiomics, and metagenomics analysis for EB. In addition, we highlight recent updates on the potential of metagenomics analysis in precision medicine for EB.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":"54 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140592061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Updated Insight into Phytomolecules and Novel Approaches used in the Management of Breast Cancer 对用于治疗乳腺癌的植物大分子和新方法的最新认识

IF 3.2 4区医学

Current drug targets Pub Date : 2024-01-13 DOI: 10.2174/0113894501277556231221072938

Zulfa Nooreen, Sudeep Tandon, Ankita Wal, Awani Kumar Rai

{"title":"An Updated Insight into Phytomolecules and Novel Approaches used in the Management of Breast Cancer","authors":"Zulfa Nooreen, Sudeep Tandon, Ankita Wal, Awani Kumar Rai","doi":"10.2174/0113894501277556231221072938","DOIUrl":"https://doi.org/10.2174/0113894501277556231221072938","url":null,"abstract":"Breast cancer is a widespread condition that kills more women from cancer-related causes than any other type of cancer globally. Women who have estrogen-dependent, initial metastatic breast cancer frequently receive treatment with surgery, radiation therapy, and chemotherapy. They may also get more specialized treatments like tamoxifen or aromatase inhibitors (anastrozole or letrozole). The World Health Organisation reported in 2012 that by 2030, breast cancer will be more common worldwide. There are several phytochemicals, such as isoflavones, coumestans, lignans, and prenylflavonoides. Isoflavones have been shown in studies to prevent the spread of breast cancer and to trigger apoptosis. Targeting BCs in metastatic breast cancer may be made possible by combining well-formulated phytochemicals in nanoparticles or other novel drug delivery agents with currently accepted endocrine and/or conventional chemotherapies. Cell signaling, regulation of cell cycles, oxidative stress action, and inflammation could be positively impacted by phytoconstituents. They have the ability to alter non-coding RNAs, to prevent the proliferation and regeneration of cancer cells. The availability of novel approaches helps in disease targeting, safety, effectiveness and efficacy. The current literature helps to know the available drugs i.e. phytoconstituents or novel drug delivery like nanoparticle, microsphere, micelles, liposomes and neosomes. The literature has been taken from PubMed, Google Scholar, SciFinder, or other internet sites.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":"36 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139463208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Potential Target of CDK6 Signaling Pathway for Cancer Treatment. CDK6 信号通路治疗癌症的潜在靶点。

IF 3 4区医学

Current drug targets Pub Date : 2024-01-01 DOI: 10.2174/0113894501313781240627062206

Rajesh Basnet, Obed Boadi Amissah, Buddha Bahadur Basnet, Rongqi Huang, Yirong Sun, Jean de Dieu Habimana, Zhiyuan Li

{"title":"Potential Target of CDK6 Signaling Pathway for Cancer Treatment.","authors":"Rajesh Basnet, Obed Boadi Amissah, Buddha Bahadur Basnet, Rongqi Huang, Yirong Sun, Jean de Dieu Habimana, Zhiyuan Li","doi":"10.2174/0113894501313781240627062206","DOIUrl":"10.2174/0113894501313781240627062206","url":null,"abstract":"Background: Cancer involves uncontrolled cell growth due to genetic mutations. Tumors can form when CDK6, a gene essential for controlling cell growth, isn't working correctly. Researchers are investigating drugs that inhibit CDK6; some of them appear promising. Nevertheless, CDK6 is advantageous and harmful to cancer because it controls other cellular processes. By inhibiting CDK6 and CDK4, CDK4/6 inhibitors offer a novel therapeutic strategy that stops cell proliferation. The study investigates the function of CDK6 in cancer, the difficulties in targeting CDK6, and possible remedies.Objective: Scientists have developed drugs designed to block CDK6 and prevent it from altering other proteins. These drugs, also known as CDK6 inhibitors, help treat cancer. Finding the best drugs for CDK6 is still tricky, though. The drugs' selectivity, potency, and cost are some difficulties. These factors depend on CDK6's structure and interactions with other proteins. The structure of CDK6 and how it influences its function and regulation are explained in this review. It also describes CDK6's function in cancer and its interaction with other molecules and proteins, which is crucial for cell division. This review also discusses the present and upcoming therapies that target CDK6, as well as how CDK6 interacts with drugs that block it.Conclusion: This review presents the structure, current research, and overview of CDK6. It also reviews the role of CDK6 in cancer, function, and regulation. Additionally, it explores its role in cancer signaling networks and its interaction with CDK6 inhibitors. Lastly, it discusses the current status and prospects of therapies targeting CDK6.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"724-739"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Perspectives in Colorectal Cancers Treatment, the Role of MicroRNAs. 结直肠癌治疗的新视角，MicroRNAs 的作用。

IF 3 4区医学

Current drug targets Pub Date : 2024-01-01 DOI: 10.2174/0113894501304351240703113651

Victoria A Belova, Liudmila V Spirina, Alexandra V Avgustinovich, Sergey G Afanas'ev, Maxim Y Volkov, Daniil I Azovsky, Alexander M Volkov, Tatyana S Klyushina

{"title":"New Perspectives in Colorectal Cancers Treatment, the Role of MicroRNAs.","authors":"Victoria A Belova, Liudmila V Spirina, Alexandra V Avgustinovich, Sergey G Afanas'ev, Maxim Y Volkov, Daniil I Azovsky, Alexander M Volkov, Tatyana S Klyushina","doi":"10.2174/0113894501304351240703113651","DOIUrl":"10.2174/0113894501304351240703113651","url":null,"abstract":"The main epidemiological and clinical data on colorectal cancer, as well as the features of molecular pathology, are discussed in the literature review. Efforts are being putto identify promising targets, particularly small non-coding nucleotide sequences, which can lead to new treatments for this disease. The discovery of significant mutations that contribute to the development of colorectal tumors is a major step in the advancement of molecular oncology, as these mutations give rise to heterogeneous tumors that differ in their origin. These mutations play a significant role in the progression of the disease and are now being targeted for treatment. The prognosis for a disease is influenced by the patient's sensitivity to antitumor therapy. However, new approaches to finding effective targets for antitumor treatments face new fundamental challenges due to clinical issues. These issues include the epigenetic regulation of markers of oncogenesis, which allows for the development of new therapeutic strategies. RNA interference, in particular, has been linked to non-copying RNA sequences such as microRNAs. These microRNAs are associated with certain processes that can influence all aspects of oncogenesis. The diversity of microRNAs allows for a differentiated approach when treating tumors in various locations.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"715-723"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141757657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of Quercetin in DNA Repair: Possible Target to Combat Drug Resistance in Diabetes. 槲皮素在 DNA 修复中的作用：对抗糖尿病抗药性的可能靶点

IF 3 4区医学

Current drug targets Pub Date : 2024-01-01 DOI: 10.2174/0113894501302098240430164446

Yaseen Hussain, Abdullah, Fazlullah Khan, Waqas Alam, Haseeba Sardar, Muhammad Ajmal Khan, Xiaoyan Shen, Haroon Khan

{"title":"Role of Quercetin in DNA Repair: Possible Target to Combat Drug Resistance in Diabetes.","authors":"Yaseen Hussain, Abdullah, Fazlullah Khan, Waqas Alam, Haseeba Sardar, Muhammad Ajmal Khan, Xiaoyan Shen, Haroon Khan","doi":"10.2174/0113894501302098240430164446","DOIUrl":"10.2174/0113894501302098240430164446","url":null,"abstract":"Diabetes Mellitus (DM) is referred to as hyperglycemia in either fasting or postprandial phases. Oxidative stress, which is defined by an excessive amount of reactive oxygen species (ROS) production, increased exposure to external stress, and an excessive amount of the cellular defense system against them, results in cellular damage. Increased DNA damage is one of the main causes of genomic instability, and genetic changes are an underlying factor in the emergence of cancer. Through covalent connections with DNA and proteins, quercetin has been demonstrated to offer protection against the creation of oxidative DNA damage. It has been found that quercetin shields DNA from possible oxidative stress-related harm by reducing the production of ROS. Therefore, Quercetin helps to lessen DNA damage and improve the ability of DNA repair mechanisms. This review mainly focuses on the role of quercetin in repairing DNA damage and compensating for drug resistance in diabetic patients. Data on the target topic was obtained from major scientific databases, including SpringerLink, Web of Science, Google Scholar, Medline Plus, PubMed, Science Direct, and Elsevier. In preclinical studies, quercetin guards against DNA deterioration by regulating the degree of lipid peroxidation and enhancing the antioxidant defense system. By reactivating antioxidant enzymes, decreasing ROS levels, and decreasing the levels of 8-hydroxydeoxyguanosine, Quercetin protects DNA from oxidative damage. In clinical studies, it was found that quercetin supplementation was related to increased antioxidant capacity and decreased risk of type 2 diabetes mellitus in the experimental group as compared to the placebo group. It is concluded that quercetin has a significant role in DNA repair in order to overcome drug resistance in diabetes.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"670-682"},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140944433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quercetin in Oncology: A Phytochemical with Immense Therapeutic Potential. 肿瘤学中的槲皮素：具有巨大治疗潜力的植物化学物质

IF 3 4区医学

Current drug targets Pub Date : 2024-01-01 DOI: 10.2174/0113894501292466240627050638

Raj Kamal, Priyanka Paul, Shubham Thakur, Sachin Kumar Singh, Ankit Awasthi

引用次数: 0